Observational Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 6, 2023; 11(31): 7610-7618
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7610
Efficacy of β2-adrenergic receptor agonist combined with corticosteroid in the treatment of children with cough variant asthma
Jun-Yi Cao, Ying-Chun Wang, Xiao-Xia Deng
Jun-Yi Cao, Ying-Chun Wang, Department of Pediatrics, The First People's Hospital of Jiangxia District, Wuhan 430200, Hubei Province, China
Xiao-Xia Deng, Department of Pediatric Respiratory, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430070, Hubei Province, China
Co-first authors: Jun-Yi Cao and Ying-Chun Wang.
Author contributions: Cao JY, and Wang YC designed the research; Deng XX performed the research; Deng XX contributed new reagents/analytic tools; Cao JY, Wang YC, and Deng XX analyzed the data; Cao JY, and Wang YC wrote the paper. Cao JY and Ying-Chun Wang contributed equally to this work as co-first authors equally to this work. The reasons for designating Cao JY and Wang YC as co-first authors are threefold. First, the research was performed as a collaborative effort, and the designation of co-first authors authorship accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the study and the resultant paper. This also ensures effective communication and management of post-submission matters, ultimately enhancing the paper's quality and reliability. Second, the overall research team encompassed authors with a variety of expertise and skills from different fields, and the designation of co-first authors best reflects this diversity. This also promotes the most comprehensive and in-depth examination of the research topic, ultimately enriching readers' understanding by offering various expert perspectives. Third, Cao JY and Wang YC contributed efforts of equal substance throughout the research process. The choice of these researchers as co-first authors acknowledges and respects this equal contribution, while recognizing the spirit of teamwork and collaboration of this study. In summary, we believe that designating Cao JY and Wang YC as co-first authors of is fitting for our manuscript as it accurately reflects our team's collaborative spirit, equal contributions, and diversity.
Institutional review board statement: The study was reviewed and approved by the first People's Hospital of Jiangxia District.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Xia Deng, MB, Nurse in charge, Department of Pediatric Respiratory, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, No. 745 Wuluo Road, Hongshan District, Wuhan 430070, Hubei Province, China. dengxiaoxia906@163.com
Received: September 19, 2023
Peer-review started: September 19, 2023
First decision: September 28, 2023
Revised: October 7, 2023
Accepted: October 26, 2023
Article in press: October 26, 2023
Published online: November 6, 2023
Processing time: 48 Days and 0.7 Hours
ARTICLE HIGHLIGHTS
Research background

The combination of inhaled corticosteroids (ICS) and long-acting β2 receptor agonist (LABA), such as salmeterol, can provide a more effective treatment strategy, but there is a lack of comprehensive research and evaluation on the efficacy of salmeterol combined with budesonide in the treatment of cough variant asthma (CVA) in children.

Research motivation

To systematically explore the efficacy of LABA salmeterol combined with ICS budesonide in the treatment of CVA in children, and to provide some clinical treatment suggestions for the treatment and clinical recovery of CVA in children.

Research objectives

The purpose of this study is to systematically evaluate the efficacy of LABA salmeterol combined with ICS budesonide in the treatment of CVA in children, and to explore the influence of the combination of the two drugs on the clinical efficacy and recovery index of asthma control in children.

Research methods

Children with CVA were selected prospectively and randomly divided into observation group (salmeterol combined with budesonide) and control group (budesonide combined with placebo). The clinical efficacy and immune function markers of the two groups were compared.

Research results

After treatment, the effect and efficiency of the two groups were improved to some extent. The symptoms of CVA in the treatment group were relieved, and the lung function index and immune marker level were also better than those in the control group.

Research conclusions

Both salmeterol combined with budesonide and budesonide alone can treat CVA to a certain extent, but the therapeutic effect of the former is significantly higher than that of the latter in symptom improvement, immune marker level and lung function level.

Research perspectives

Salmeterol combined with budesonide is an effective method to treat CVA disease, which is worth popularizing in clinic.